Abstract
Silymarin flavonolignans are well-known agents that typically possess antioxidative, anti-inflammatory, and hepatoprotective functions. Recent studies have also documented the antiviral activities of silymarin and its derivatives against several viruses, including the flaviviruses (hepatitis C virus and dengue virus), togaviruses (Chikungunya virus and Mayaro virus), influenza virus, human immunodeficiency virus, and hepatitis B virus. This review will describe some of the latest preclinical and clinical studies detailing the antiviral profiles of silymarin and its derivatives, and discuss their relevance for antiviral drug development.
Original language | English |
---|---|
Article number | 1552 |
Journal | Molecules |
Volume | 24 |
Issue number | 8 |
DOIs | |
Publication status | Published - Apr 19 2019 |
Bibliographical note
Funding Information:This research was supported in part by funding from the Ministry of Science and Technology of Taiwan (MOST107-2320-B-038-034-MY3) and a grant from Chi-Mei Medical Center and Taipei Medical University (108CM-TMU-02). C.-H.L. is a recipient of the Canadian Network on Hepatitis C (CanHepC) PhD Fellowship.
Publisher Copyright:
© 2019 by the authors.
ASJC Scopus Subject Areas
- Analytical Chemistry
- Chemistry (miscellaneous)
- Molecular Medicine
- Pharmaceutical Science
- Drug Discovery
- Physical and Theoretical Chemistry
- Organic Chemistry